Sarcoma Oncology Center

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Sarcoma12 trials
• Colorectal cancer5 trials
• Lung cancer5 trials
• Ovarian cancer4 trials
• Head and neck cancer3 trials
• Liver and biliary tract cancer3 trials
• Melanoma3 trials
• Pancreatic cancer3 trials
• Endometrial cancer2 trials
• Gastric and oesophageal cancer2 trials
• Kidney cancer2 trials
• Neuroendocrine tumours2 trials
• and 6 more

Phase

• Phase 15 trials
• Phase 1/25 trials
• Phase 34 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Recruiting9 trials
• Completed5 trials
• Active, not recruiting4 trials
• Terminated2 trials

Lead sponsor

• Boehringer Ingelheim3 trials
• Inhibrx Biosciences, Inc2 trials
• Sonnet BioTherapeutics2 trials
• Advenchen Laboratories, LLC1 trial
• Coherus Oncology, Inc.1 trial
• and 11 more

Running trials

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

  NCT06493552· Phase 2/3· Vasgene Therapeutics, Inc· Source

  Contact: Victoria Chua

• Recruiting

  A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  NCT06789172· Phase 1· Epkin· Source

  Contact: Chawla

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Coherus Oncology, Inc.· Source

• Recruiting

  A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

  NCT06263231· Phase 3· Intensity Therapeutics, Inc.· Source

  Contact: Sant P Chawla, MD

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

  Contact: Neal Chawla, MD (principal investigator)

• Recruiting

  FOG-001 in Locally Advanced or Metastatic Solid Tumors

  NCT05919264· Phase 1/2· Parabilis Medicines, Inc.· Source

  Contact: Sant Chawla, MD

• Active, not recruiting

  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

  NCT05585320· Phase 1/2· Immuneering Corporation· Source

• Active, not recruiting

  Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

  NCT05352750· Phase 1· Sonnet BioTherapeutics· Source

• Recruiting

  Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

  NCT03886311· Phase 2· Sarcoma Oncology Research Center, LLC· Source

  Contact: Victoria Chua

• Recruiting

  Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

  NCT03715933· Phase 1· Inhibrx Biosciences, Inc· Source

  Contact: Victoria Chua-Alcala

• Recruiting

  Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

  NCT03016819· Phase 3· Advenchen Laboratories, LLC· Source

  Contact: Victoria Study Coordinator

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sarcoma5 recruiting
• Colorectal cancer3 recruiting
• Head and neck cancer2 recruiting
• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study of DF6215 in Patients With Advanced Solid Tumors

  NCT06108479· Phase 1· Dragonfly Therapeutics· Source

• Terminated

  Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

  NCT05756907· Phase 1/2· Sonnet BioTherapeutics· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

  NCT05043649· Phase 1· Monopar Therapeutics· Source

• Completed

  Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

  NCT04887298· Phase 1/2· Moleculin Biotech, Inc.· Source

• Completed

  Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

  NCT02611024· Phase 1/2· PharmaMar· Source